SF3B1 and myelodysplastic syndrome: SF3B1 mutation was observed in 90% of patients with myelodysplastic syndrome (MDS) with ring sideroblasts, which is characterized by anemia, iron-rich mitochondria surrounding the nuclei of erythroid precursors, and a favorable prognosis (18–21).